Literature DB >> 30050766

Appropriate screening intervals in low-dose CT lung cancer screening.

Marjolein A Heuvelmans1,2, Matthijs Oudkerk1.   

Abstract

Lung cancer screening by low-dose chest CT (LDCT) is now being implemented in the United States, and in Europe it was recently recommended to start planning for implementation. Current lung cancer screening programmes include up to 25 annual LDCTs, plus shorter-term follow-up LDCTs when indicated. However, the choice of a yearly CT scan has not been based on biological mechanisms, and it is questionable whether all persons eligible for lung cancer screening require annual screening. A tailored approach in screening programs to balance potential harms and benefits from screening becomes more and more important when lung cancer screening is performed more widespread. If lung cancer screening participants can be identified at mid-high lung cancer risk that can be followed safely by prolonged screening intervals, reduction of possible physiological harms, radiation exposure and costs can be expected. Different randomized controlled lung cancer screening studies have shown that the baseline screen result can be used to identify a subset of participants with a low 2-year lung cancer probability. These participants may be safely followed after a prolonged screening interval with the optimal screening interval probably between 1 and 2 years until their risk profile changes. In case a new pulmonary nodule appears at subsequent screening, or a small baseline nodule starts growing, participants should always return to annual LDCT screening after the appropriate workup.

Entities:  

Keywords:  Lung cancer; computed tomography; screen interval; screening

Year:  2018        PMID: 30050766      PMCID: PMC6037974          DOI: 10.21037/tlcr.2018.05.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  32 in total

1.  Improving selection criteria for lung cancer screening. The potential role of emphysema.

Authors:  Pablo Sanchez-Salcedo; David O Wilson; Juan P de-Torres; Joel L Weissfeld; Juan Berto; Arantzazu Campo; Ana B Alcaide; Jesús Pueyo; Gorka Bastarrika; Luis M Seijo; Maria J Pajares; Ruben Pio; Luis M Montuenga; Javier J Zulueta
Journal:  Am J Respir Crit Care Med       Date:  2015-04-15       Impact factor: 21.405

Review 2.  Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening.

Authors:  Joan E Walter; Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2017-02

3.  Risk stratification based on screening history: the NELSON lung cancer screening study.

Authors:  Uraujh Yousaf-Khan; Carlijn van der Aalst; Pim A de Jong; Marjolein Heuvelmans; Ernst Scholten; Joan Walter; Kristiaan Nackaerts; Harry Groen; Rozemarijn Vliegenthart; Kevin Ten Haaf; Matthijs Oudkerk; Harry de Koning
Journal:  Thorax       Date:  2017-03-30       Impact factor: 9.139

4.  Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial.

Authors:  Ugo Pastorino; Marta Rossi; Valentina Rosato; Alfonso Marchianò; Nicola Sverzellati; Carlo Morosi; Alessandra Fabbri; Carlotta Galeone; Eva Negri; Gabriella Sozzi; Giuseppe Pelosi; Carlo La Vecchia
Journal:  Eur J Cancer Prev       Date:  2012-05       Impact factor: 2.497

5.  Selection criteria for lung-cancer screening.

Authors:  Martin C Tammemägi; Hormuzd A Katki; William G Hocking; Timothy R Church; Neil Caporaso; Paul A Kvale; Anil K Chaturvedi; Gerard A Silvestri; Tom L Riley; John Commins; Christine D Berg
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

6.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

7.  Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.

Authors:  Nanda Horeweg; Ernst Th Scholten; Pim A de Jong; Carlijn M van der Aalst; Carla Weenink; Jan-Willem J Lammers; Kristiaan Nackaerts; Rozemarijn Vliegenthart; Kevin ten Haaf; Uraujh A Yousaf-Khan; Marjolein A Heuvelmans; Erik Thunnissen; Matthijs Oudkerk; Willem Mali; Harry J de Koning
Journal:  Lancet Oncol       Date:  2014-10-01       Impact factor: 41.316

8.  Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Authors:  Martin C Tammemagi; Heidi Schmidt; Simon Martel; Annette McWilliams; John R Goffin; Michael R Johnston; Garth Nicholas; Alain Tremblay; Rick Bhatia; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; David M Hwang; Francis Laberge; Michel Gingras; Sergio Pasian; Christian Couture; John R Mayo; Paola V Nasute Fauerbach; Sukhinder Atkar-Khattra; Stuart J Peacock; Sonya Cressman; Diana Ionescu; John C English; Richard J Finley; John Yee; Serge Puksa; Lori Stewart; Scott Tsai; Ehsan Haider; Colm Boylan; Jean-Claude Cutz; Daria Manos; Zhaolin Xu; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Harmanjatinder S Sekhon; Paul Burrowes; Paul MacEachern; Stefan Urbanski; Don D Sin; Wan C Tan; Natasha B Leighl; Frances A Shepherd; William K Evans; Ming-Sound Tsao; Stephen Lam
Journal:  Lancet Oncol       Date:  2017-10-18       Impact factor: 41.316

9.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

10.  Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

Authors:  Edward F Patz; Erin Greco; Constantine Gatsonis; Paul Pinsky; Barnett S Kramer; Denise R Aberle
Journal:  Lancet Oncol       Date:  2016-03-18       Impact factor: 41.316

View more
  9 in total

Review 1.  Low Dose CT for Lung Cancer Screening: The Background, the Guidelines, and a Tailored Approach to Patient Care.

Authors:  Emily Tylski; Mala Goyal
Journal:  Mo Med       Date:  2019 Sep-Oct

Review 2.  Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Authors:  Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field
Journal:  Nat Rev Clin Oncol       Date:  2020-10-12       Impact factor: 66.675

Review 3.  Understanding the harm of low-dose computed tomography radiation to the body (Review).

Authors:  Hai-Min Shi; Zhi-Chao Sun; Fang-He Ju
Journal:  Exp Ther Med       Date:  2022-06-23       Impact factor: 2.751

4.  Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification.

Authors:  Matthew Fabbro; Kirah Hahn; Olivia Novaes; Mícheál Ó'Grálaigh; James F O'Mahony
Journal:  Pharmacoecon Open       Date:  2022-08-30

5.  Radiological manifestations, histological features and surgical outcomes of pulmonary meningothelial proliferation: a case series and rethinking.

Authors:  Dong Lin; Yangli Yu; Hao Wang; Yong Fang; Jun Yin; Yaxing Shen; Lijie Tan
Journal:  Transl Lung Cancer Res       Date:  2020-08

6.  Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime.

Authors:  Zhe Zhang; Shuangshuang Lu; Louisa S Chard Dunmall; Zhizhong Wang; Zhenguo Cheng; Zhongxian Zhang; Wenli Yan; Yongchao Chu; Dongling Gao; Na Wang; Yang Li; Jiwei Wang; Yuenan Li; Yupei Ji; Danyang Shan; Keke Li; Panpan Wang; Yunshu Dong; Jianzeng Dong; Nick R Lemoine; Duanqing Pei; Lirong Zhang; Yaohe Wang
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

Review 7.  Latest CT technologies in lung cancer screening: protocols and radiation dose reduction.

Authors:  Marleen Vonder; Monique D Dorrius; Rozemarijn Vliegenthart
Journal:  Transl Lung Cancer Res       Date:  2021-02

8.  Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups.

Authors:  Mohamed N M T Al Khayat; Job F H Eijsink; Maarten J Postma; Ewoudt M W van de Garde; Marinus van Hulst
Journal:  Eur J Health Econ       Date:  2022-01-05

Review 9.  Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion.

Authors:  John K Field; Harry deKoning; Mattijs Oudkerk; Sadia Anwar; James Mulshine; Ugo Pastorino; Wilfried Eberhardt; Helmut Prosch
Journal:  ESMO Open       Date:  2019-10-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.